NVO has been in the news 375% more than usual

NVO has been in the news recently: President Trump launched TrumpRx.gov to promote discounted weight‑loss drugs, citing offers like about $350 per month versus roughly $1,000 for Ozempic — the GLP‑1 injectable made by Novo Nordisk — with discounts said to come from 14 drugmakers. Pfizer’s CEO noted broad industry participation, saying the U.S. is 4% of the world population but 13% of drug use and that 16 of 17 firms had signed, highlighting growing competition in the GLP‑1/weight‑loss market where Novo Nordisk is a leading supplier.